Kraig Biocraft Labs Achieves Early Success In Spider Silk Production
Kraig Biocraft Laboratories, Inc., the biotechnology company focused on the development and commercialization of spider silk, recently announced the early start to the production season with the successful manufacture and delivery of the most recent batch of recombinant spider silk. Silk from this production cycle was processed into finished reeled raw silk and received on-site by the company’s senior management this week.
The delivery of this silk further reinforces the company’s production model. With this success, the company will now accelerate its plans for the upcoming 2024 production season and beyond.
“I am very excited to have produced this small batch ahead of our upcoming field trials scheduled for this spring. This early production bodes very well for the pending trials, and indicates to me that we are well on track to meet our 2024 production targets,” said CEO and founder Kim Thompson. “The purpose of the recently completed production batch was to test our production model. The purpose of the upcoming field trials is to gain data from hybrids which we have developed over the last 12 months. Having those two pieces working together is key to commercial scale production,” Thompson added.
